Lactobacillus brevis
Lactobacillus brevis
Also known as: L. brevis, Lactobacillus brevis probiotic
This ingredient is classified as unclassified risk.
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Lactobacillus brevis is a lactic acid bacterium used in probiotic formulas for GI and immune support. It is naturally present in fermented foods. Generally very safe and well tolerated. Standard probiotic safety caveats apply: use caution in severely immunocompromised individuals or those with central venous catheters due to very rare risk of bacteremia.
Biological and Chemical Classification
- Scientific Name
- Lactobacillus brevis
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Probiotics
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Lactobacillus brevis indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 ივნ 2026, 12:02
Evidence Distribution
-
Observational / other LOW evidence YELLOWIn Vitro Phenotypic Screening and MALDI-TOF Identification of Lactic Acid Bacteria Isolated from Feces of Suckling Piglets with Antibacterial Activity. ↗Awaiwanont N et al.. In Vitro Phenotypic Screening and MALDI-TOF Identification of Lactic Acid Bacteria Isolated from Feces of Suckling Piglets with Antibacterial Activity.. Animals (Basel). 2026. PMID:42193717.PMID 42193717 ↗Journal Animals (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42193717/
-
Observational / other LOW evidence YELLOWIn vitro Evaluation of Immunomodulatory and Antioxidant Potential of Isolated Lactic Acid Bacteria from Iranian Dairy Products: An Insight into beneficial potential… ↗Mahooti M et al.. In vitro Evaluation of Immunomodulatory and Antioxidant Potential of Isolated Lactic Acid Bacteria from Iranian Dairy Products: An Insight into beneficial potential of cheese-derived isolates.. Probiotics Antimicrob Proteins. 2026. PMID:42118444.PMID 42118444 ↗Journal Probiotics Antimicrob ProteinsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42118444/
-
Observational / other LOW evidence YELLOWSelenized Probiotic L. brevis 23017 Alleviates Colitis by Modulating the Nrf2-GPX4 Axis to Inhibit Ferroptosis. ↗Zhuang Y et al.. Selenized Probiotic L. brevis 23017 Alleviates Colitis by Modulating the Nrf2-GPX4 Axis to Inhibit Ferroptosis.. Biol Trace Elem Res. 2026. PMID:42095958.PMID 42095958 ↗Journal Biol Trace Elem ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42095958/
-
Observational / other LOW evidence YELLOWEffects of Host-Specific Multi-Lactic Acid Bacterial Probiotics on Performance, Carcass Traits, Meat Quality, and Gut Microbiome in Fattening Pigs. ↗Sahatsanon K et al.. Effects of Host-Specific Multi-Lactic Acid Bacterial Probiotics on Performance, Carcass Traits, Meat Quality, and Gut Microbiome in Fattening Pigs.. Vet Sci. 2026. PMID:42076694.PMID 42076694 ↗Journal Vet SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42076694/
-
Observational / other LOW evidence YELLOWSynergistic dietary supplements of Lactobacillus brevis and trans-cinnamic acid improved growth, immune response, and disease resistance in common carp. ↗Alinia M et al.. Synergistic dietary supplements of Lactobacillus brevis and trans-cinnamic acid improved growth, immune response, and disease resistance in common carp.. Sci Rep. 2026. PMID:42014760.PMID 42014760 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42014760/
-
Observational / other LOW evidence YELLOWExtension of Lifespan and Amelioration of Alzheimer's Disease Phenotypes by Genetic Manipulation of Mitochondrial NAD(+)/NADH Ratio. ↗Rimal S et al.. Extension of Lifespan and Amelioration of Alzheimer's Disease Phenotypes by Genetic Manipulation of Mitochondrial NAD(+)/NADH Ratio.. Aging Dis. 2026. PMID:41980212.PMID 41980212 ↗Journal Aging DisYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41980212/
-
Observational / other LOW evidence YELLOWThe mechanisms underlying ester enhancement and higher alcohol reduction in Chi-flavor base liquor brewing via Limosilactobacillus fermentum fortification: A multi-omics investigation. ↗Liu G et al.. The mechanisms underlying ester enhancement and higher alcohol reduction in Chi-flavor base liquor brewing via Limosilactobacillus fermentum fortification: A multi-omics investigation.. Food Microbiol. 2026. PMID:41963043.PMID 41963043 ↗Journal Food MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41963043/
-
Observational / other LOW evidence YELLOWA review of dominant lactic acid bacteria strains and inoculation fermentation for fermented mustard plant. ↗Zhou Y et al.. A review of dominant lactic acid bacteria strains and inoculation fermentation for fermented mustard plant.. Front Microbiol. 2026. PMID:41939714.PMID 41939714 ↗Journal Front MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41939714/
-
Observational / other LOW evidence YELLOWThe Therapeutic Administration of Lactobacillus brevis ZG2488 Suppresses Influenza A Virus Replication Through a Viability-Dependent Host Transcriptional Modulation Mechanism. ↗Chen M et al.. The Therapeutic Administration of Lactobacillus brevis ZG2488 Suppresses Influenza A Virus Replication Through a Viability-Dependent Host Transcriptional Modulation Mechanism.. Microorganisms. 2026. PMID:41900346.PMID 41900346 ↗Journal MicroorganismsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41900346/
-
Observational / other LOW evidence YELLOWEffects of Sequential Fermentation with Saccharomyces bayanus and Lactobacillus brevis on the Metabolite Composition and Antioxidant Activity of Chinese Yam Juice. ↗Mushtaq A et al.. Effects of Sequential Fermentation with Saccharomyces bayanus and Lactobacillus brevis on the Metabolite Composition and Antioxidant Activity of Chinese Yam Juice.. Foods. 2026. PMID:41897777.PMID 41897777 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41897777/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Lactobacillus brevis. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Lactobacillus brevis
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.